NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock Soars

NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock Soars

Clinical-stage immunotherapy company Nantkwest Inc (NKreports positive interim data on survival rates in the Metastatic Pancreatic Cancer QUILT 88 trial on Wednesday.

What Happened: Nantkwest said that early interim results of its PD-L1 t-haNK protocols showing median survival rates more than doubled that of the historical rate in patients with advanced metastatic pancreatic cancer for which no other FDA-approved treatment exists.

The data validates the theory that survival rates could be improved without high-dose chemotherapy by orchestrating natural killer and T-cell therapy. 

The trials were based on the original Cancer Moonshot hypothesis, a collaborative trial involving the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including Nantkwest, ImmunityBioBristol-Myers Squibb Co (BMY)-owned Celgene, and Pfizer Inc. (PFE).

Interim Study Results: Moonshot QUILT trials of haNK combined with PD-L1 inhibitor avelumab were completed in 2019, showed that the median overall survival rate more than doubled in the 12-patient study compared to historical controls. Details here.

Four out of five patients who had not yet reached median survival time (three months) are alive 8-16 months since beginning treatment on these expanded protocols when replacing haNK and PD-L1 inhibitor avelumab with PD-L1 t-haNK.

A single-arm Phase 2 QUILT 88 study was initiated in October 2020, the primary endpoint for which is overall survival, and 15 out of 18 (83%) of patients enrolled with second-line or greater pancreatic cancer remain alive to date.

A randomized Phase 2 QUILT 88 study for first- and second-line metastatic pancreatic cancer is actively enrolling at three sites.

Why It Matters: "These observations confirmed the promise of our hypothesis that activating the patient's own immune system with low-dose chemo immunomodulation therapy could improve outcomes," said Patrick Soon-Shiong, M.D., Chairman, and CEO of ImmunityBio.

1 2
View single page >> |

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.